Home Capital Broker's Calls

Tianjin Zhongxin Pharma on its way to a stellar 2018 & beyond, says UOB

Michelle Zhu
Michelle Zhu4/2/2018 11:11 AM GMT+08  • 2 min read
Tianjin Zhongxin Pharma on its way to a stellar 2018 & beyond, says UOB
SINGAPORE (Apr 2): UOB Kay Hian is keeping Tianjin Zhongxin Pharmaceutical Group at “buy” with a higher target price of US$1.66 ($2.17), pegged to peer average of 14.1 times FY18 earnings.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Apr 2): UOB Kay Hian is keeping Tianjin Zhongxin Pharmaceutical Group at “buy” with a higher target price of US$1.66 ($2.17), pegged to peer average of 14.1 times FY18 earnings.

This comes after Tianjin Zhongxin Pharma exceeded expectations in 4Q17 due to a net profit surge, bringing full-year PATMI to RMB473.3 million, 4.5% above UOB’s full-year forecast on higher 4Q blended gross margin after factoring in a price hike for the group’s key product, “Su Xiao Jiu Xin” pills.

In a Monday report, lead analyst Edison Chen says Tianjin Zhongxin Pharma's stellar 4Q17 results are but only the beginning of a multi-year growth story for the group.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now